SNAP-8 vs Orforglipron
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
SNAP-8GLP-1 / Weight Loss Agonists
Orforglipron- Summary
- SNAP-8 is a synthetic octapeptide cosmetic ingredient that reduces the depth of expression lines and wrinkles by competitively inhibiting the SNARE complex involved in acetylcholine release at neuromuscular junctions, providing a topical 'Botox-like' effect.
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Half-Life
- N/A — topical application; local effect duration depends on formulation
- ~12 hours (once-daily oral dosing)
- Admin Route
- Topical
- Oral
- Research
- —
- —
- Typical Dose
- 3–10% concentration in formulation
- 12 mg → 24 mg → 36 mg → 45 mg
- Frequency
- 1–2x daily
- Once daily
- Key Benefits
- Reduces depth of dynamic expression wrinkles
- Smooths forehead lines, crow's feet, glabellar lines
- Non-invasive topical Botox alternative
- Can be incorporated into serums, creams, eye contour products
- Reduces muscle contraction without paralysis
- Improves skin texture and firmness over time
- Complements other anti-aging peptides (Argireline, Matrixyl)
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Side Effects
- Generally excellent tolerability
- Rare: mild redness in sensitive individuals
- Not suitable for injection (topical use only)
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Stacks With
- —
- —